主要作者

摘要標(biāo)題

報(bào)告詳情(CEST)

抗體偶聯(lián)藥物

Harbeck, N

DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan
alone (T-DXd) or followed by paclitaxel + trastuzumab +
pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+
early breast cancer (eBC)

Abstract #291O

Presidential 1

18 October 2025

4:30 PM

Geyer, C

Trastuzumab deruxtecan (T-DXd) vs trastuzumab
emtansine (T-DM1) in patients (pts) with high-risk human
epidermal growth factor receptor 2–positive (HER2+)
primary breast cancer (BC) with residual invasive disease
after neoadjuvant therapy (tx): Interim analysis of
DESTINY-Breast05

Abstract #LBA1

Presidential 1

18 October 2025

4:52 PM

Dent, R.

First-line (1L) datopotamab deruxtecan (Dato-DXd) vs
chemotherapy in patients with locally recurrent inoperable
or metastatic triple-negative breast cancer (mTNBC) for
whom immunotherapy was not an option: Primary results
from the randomised, phase 3 TROPION-Breast02 trial

Abstract #LBA21

Proffered Paper Session

19 October 2025

9:25 AM

Loibl, S

Trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane
+ trastuzumab + pertuzumab (THP) for patients with
HER2+ advanced/metastatic breast cancer: additional
analysis of DESTINY-Breast09 in key subgroups of interest

Abstract #LBA18

Proffered Paper Session

19 October 2025

8:30 AM

Rha, SY

Datopotamab deruxtecan (Dato-DXd) + rilvegostomig
(rilve) in patients (pts) with locally advanced or metastatic
urothelial cancer (a/mUC): Results from the phase 2
TROPION-PanTumor03 study

Abstract #3072MO

Mini Oral Session

17 October 2025

4:10 PM

Oaknin, A

First-in-human study of AZD5335, a folate receptor α
(FRα)-targeted antibody-drug conjugate, in patients with
platinum-resistant recurrent ovarian cancer

Abstract #1065MO

Mini Oral Session

19 October 2025

10:53 AM

Schmid, P

Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as
first-line (1L) treatment (tx) for unresectable locally
advanced/metastatic triple-negative breast cancer
(a/mTNBC): Final results from the phase 1b/2 BEGONIA
study

Abstract #555MO

Mini Oral Session

20 October 2025

10:50 AM

Raghav, K

Trastuzumab deruxtecan (T DXd) in patients (pts) with
HER2-positive (HER2+) metastatic colorectal cancer
(mCRC): Final analysis of DESTINY-CRC02, a
randomized, phase 2 trial

Abstract #737P

Poster Session

Peng, Z

Trastuzumab deruxtecan (T-DXd) in patients (pts) with
HER2+ gastric cancer (GC) or gastroesophageal junction
adenocarcinoma (GEJA) who received prior anti-HER2
treatment (Tx) other than / in addition to trastuzumab in
DESTINY-Gastric06 (DG-06)

Abstract #2105P

Poster Session

Shen, L

Risk of hepatitis B virus reactivation (HBVr) in patients
(pts) with past or resolved HBV or inactive chronic HBV
infection treated with trastuzumab deruxtecan (T-DXd) in
the DESTINY-Gastric06 (DG-06) trial

Abstract #2175P

Poster Session

Pietrantonio, F

Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM)
plus paclitaxel (PTX) in second-line (2L) treatment of
patients (pts) with HER2+ unresectable/metastatic gastric
cancer (GC)/gastroesophageal junction adenocarcinoma
(GEJA): Additional data from DESTINY-Gastric04 (DG-04)

Abstract #2099P

Poster Session

Makker, V

Trastuzumab deruxtecan (T-DXd) for pretreated patients
(pts) with HER2-expressing solid tumors: DESTINY-
PanTumor02 (DP-02) Part 1 final analysis

Abstract #957P

Poster Session

Lee, J-Y

Trastuzumab deruxtecan (T-DXd) in pretreated patients
(pts) with HER2-expressing solid tumors: exploratory
biomarker analysis of DESTINY-PanTumor02 (DP-02) Part
1

Abstract #145P

Poster Session

免疫腫瘤學(xué)

Tabernero, J

MATTERHORN Phase III trial of Imfinzi (durvalumab)
perioperative Imfinzi (durvalumab) plus FLOT
chemotherapy in patients with resectable, early-stage and
locally advanced gastric and gastroesophageal junction
(GEJ) cancers

Abstract #LBA81

Proffered Paper Session

17 October 2025

2:00 PM

De Santis, M

Durvalumab (D) in Combination with Bacillus Calmette-
Guérin (BCG) for BCG-naïve, High-risk Non-muscle-
invasive Bladder Cancer (NMIBC): Results from the Phase
3, Open-label, Randomised POTOMAC Trial

Abstract #LBA108

Proffered Paper Session

17 October 2025

2:10 PM

Larkin, J

First results from RAMPART: An international phase 3
randomised-controlled trial of adjuvant durvalumab
monotherapy or combined with tremelimumab for resected
primary renal cell carcinoma (RCC) led by MRC CTU at
UCL

Abstract #LBA93

Proffered Paper Session

18 October 2025

9:20 AM

Aghajanian, C

Durvalumab + paclitaxel/carboplatin + bevacizumab
followed by durvalumab, bevacizumab + olaparib
maintenance in patients with newly diagnosed non-tBRCA-
mutated advanced ovarian cancer: final overall survival
from DUO-O/ENGOT-ov46/GOG-3025

Abstract #LBA44

Mini Oral Session

19 October 2025

11:31 AM

Goss, G

CCTG BR.31: Adjuvant durvalumab (D) in resected non-
small-cell lung cancer (NSCLC): final overall survival (OS)
and minimal residual disease (MRD) analyses

Abstract #LBA68

Mini Oral Session

20 October 2025

3:20 PM

Heymach, J

Association of radiomic features ± on-treatment ctDNA
detection with treatment outcomes in patients with
resectable NSCLC: exploratory analyses from AEGEAN

Abstract #LBA70

Mini Oral Session

20 October 2025

3:50 PM

Wermke, M

Tarlatamab with first-line chemoimmunotherapy for
extensive stage small cell lung cancer (ES-SCLC):
DeLLphi-303 study

Abstract #2757O

Proffered Paper Session

18 October 2025

8:30 AM

Loibl, S

Durvalumab in Combination with Neoadjuvant
Chemotherapy in Early Triple-Negative Breast Cancer
(TNBC) – Long-term Analysis from the GeparNuevo Trial

Abstract #292MO

Mini Oral Session

19 October 2025

10:15 AM

Van der Heijden, M

Health-related quality of life (HRQoL) from the NIAGARA
trial of perioperative durvalumab (D) plus neoadjuvant
chemotherapy (NAC) in muscle-invasive bladder cancer
(MIBC)

Abstract #3069MO

Mini Oral Session

17 October 2025

4:00 PM

Sangro, B

Pooled efficacy and safety outcomes with tremelimumab
plus durvalumab in participants (pts) with unresectable
hepatocellular carcinoma (uHCC) from the combined
China extension and global cohorts in the Phase 3
HIMALAYA study

Abstract #1494P

Poster Session

Westin, S

Durvalumab plus carboplatin/paclitaxel followed by
durvalumab for endometrial cancer: Tumour mutational
burden-high subpopulation efficacy analyses from the
DUO-E trial

Abstract #1117P

Poster Session

Leal, TA

Global quantitative assessment of multidisciplinary team
(MDT) care in early-stage NSCLC

Abstract #1794P

Poster Session

Reck, M

Neoadjuvant durvalumab (D) + chemotherapy (CT)
followed by either surgery (Sx) and adjuvant D or CRT and
consolidation D in patients (pts) with resectable or
borderline resectable stage IIB–IIIB NSCLC: interim
analysis (IA) of the phase 2 MDT-BRIDGE study

Abstract #LBA65

Proffered Paper Session

18 October 2025

9:15 AM

Maruki, Y

CELEBRATE Study (JCOG2107E): A Multicenter, Open-
label, Phase III Trial of Etoposide, Carboplatin, and
Durvalumab in First-line Treatment of Unresectable or
Recurrent Digestive NEC

Abstract #1734TiP

Poster Session

Oudard, S

A phase IIIb, open-label, single-arm, global study of
perioperative durvalumab (D) with neoadjuvant dose-
dense methotrexate, vinblastine, doxorubicin, and cisplatin
(ddMVAC) or gemcitabine/cisplatin (gem/cis) in patients
with muscle-invasive bladder cancer (MIBC) (NIAGARA-2)

Abstract #3133eTiP

ePoster Session

雙特異性抗體

Chul Cho, B

Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT
Bispecific Antibody, for Checkpoint Inhibitor (CPI)-Naïve
Metastatic Non-Small-Cell Lung Cancer (mNSCLC):
ARTEMIDE-01

Abstract #1853MO

Mini Oral Session

20 October 2025

10:25 AM

Slomovitz, BM

A randomized Phase 3 study of first-line (1L) trastuzumab
deruxtecan (T-DXd) with rilvegostomig or pembrolizumab
in patients with HER2-expressing, mismatch repair-
proficient (pMMR), primary advanced or recurrent
endometrial cancer (EC): DESTINY-Endometrial01/GOG-
3098/ENGOT-EN24

Abstract #1223TiP

Poster Session

Naidoo, J

ARTEMIDE-Lung04: A Phase 3, randomised, double-blind,
global study of rilvegostomig or pembrolizumab
monotherapy as first-line (1L) treatment for patients with
metastatic non-small cell lung cancer (mNSCLC) and

programmed cell death ligand-1 (PD-L1) expression ≥50%

Abstract #2025TiP

Poster Session

腫瘤驅(qū)動(dòng)因子和耐藥性

Jänne, PA

FLAURA2: exploratory overall survival (OS) analysis in
patients (pts) with poor prognostic factors treated with
osimertinib (osi) ± platinum-pemetrexed chemotherapy
(CTx) as first-line (1L) treatment for EGFR-mutated
(EGFRm) advanced NSCLC

Abstract #LBA77

Proffered Paper Session

17 October 2025

4:56 PM

Mayer, E

Patient-reported outcomes (PROs) from the SERENA-6
trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i)
for emergent ESR1m during first-line (1L) endocrine-based
therapy and ahead of disease progression in patients (pts)
with HR+/HER2- advanced breast cancer (ABC)

Abstract #486MO

Mini Oral Session

20 October 2025

10:25 AM

Arriola, E

Molecular residual disease (MRD) analysis from the
LAURA study of osimertinib (osi) in unresectable (UR)
stage III EGFR-mutated (EGFRm) NSCLC

Abstract #1817MO

Mini Oral Session

20 October 2025

2:55 PM

Park, YH

Visual symptom questionnaire results from SERENA-6, a
Phase 3 study of switch to camizestrant (CAMI) + CDK4/6
inhibitor (CDK4/6i) at emergence of ESR1m during first-
line (1L) therapy for patients (pts) with HR+/HER2-
advanced breast cancer (ABC)

Abstract #528P

Poster Session

Chu, Q

SAVANNAH: Safety and tolerability of osimertinib (osi) +
savolitinib (savo) in EGFRm advanced NSCLC with MET
overexpression and/or amplification (OverExp/Amp)
following disease progression on osi

Abstract #1955P

Poster Session

Rotow, J

MET testing and treatment (tx) sequencing after
progression on first line (1L) osimertinib (osi) in patients
(pts) with EGFRm advanced NSCLC and acquired MET
overexpression and/or amplification (OverExp/Amp):
Interim analysis of a global real world (rw) study

Abstract #1967P

Poster Session

Yu, Y

ctDNA analysis in phase 3 SACHI trial: Savolitinib (savo)
plus osimertinib (osi) versus chemotherapy (chemo) in
MET-amplified (METamp) advanced NSCLC after disease
progression (PD) on EGFR tyrosine kinase inhibitor (TKI)

Abstract #1954P

Poster Session

DNA損傷應(yīng)答

Azad, AA

First interim efficacy analysis of the Phase 1/2 PETRANHA
trial of saruparib + androgen receptor pathway inhibitors
(ARPI) in patients (pts) with metastatic prostate cancer
(mPC)

Abstract #2384MO

Mini Oral Session

17 October 2025

2:35 PM

Fizazi, K

A Phase 3 study of capivasertib (capi) + abiraterone (abi)
vs placebo (pbo) + abi in patients (pts) with PTEN deficient
de novo metastatic hormone-sensitive prostate cancer
(mHSPC): CAPItello-281

Abstract #2383O

Proffered Paper Session

19 October 2025

11:19 AM

Rugo, HS

Capivasertib with fulvestrant as first- and second-line
endocrine therapy in PIK3CA/AKT1/PTEN-altered
hormone receptor-positive advanced breast cancer:
Subgroup analysis from the Phase 3 CAPItello-291 trial

Abstract #526P

Poster Session

Gao, Q

Final overall survival (OS) analysis of L-MOCA: olaparib
maintenance monotherapy in patients (pts) with platinum-
sensitive relapsed ovarian cancer (PSR OC)

Abstract #1090P

Poster Session

AI驅(qū)動(dòng)的臨床試驗(yàn)

Gonuguntla, HK

Real-World Validation of AI-defined Lung Nodule
Malignancy Score (qXR-LNMS) in Predicting Risk of Lung
Cancer: Interim results from Phase 2

Abstract #2978P

Poster Session